Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC)

Autor:	Domenica Lorusso, R. De Vincenzo, Giovanni Scambia, Nausica Trivellizzi, Giovanni Citterio, Antonella Pietragalla, Antonio Lambiase, M. Di Stefano, S. Montoli, Vanda Salutari, Giulia Amadio, Claudio Bordignon, G. Mangili
Rok vydání:	2011
Předmět:	chemistry.chemical_classification Gynecology Cancer Research medicine.medical_specialty business.industry Phases of clinical research Peptide medicine.disease Oncology chemistry NGR-hTNF medicine Cancer research Doxorubicin Tumor necrosis factor alpha Ovarian cancer business medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:5022-5022
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.5022
Popis:	5022 Background: NGR-hTNF consists of tumor necrosis factor fused with the peptide NGR, which selectively binds to a CD13 overexpressed on tumor blood vessels. NGR-hTNF is able to increase the intr...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f83c5480e355552906fc6b6f82c972b0 https://doi.org/10.1200/jco.2011.29.15_suppl.5022 Zobrazit plný text záznamu